MAM
DNLI icon

Mark Asset Management’s Denali Therapeutics DNLI Stock Holding History

Mark Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-40,370
Closed -$1.8M – 51
2021
Q4 		$1.8M Buy
40,370
+19,841
+97% +$940K 0.2% 44
2021
Q3 		$1.04M Sell
20,529
-18,310
-47% -$1.03M 0.11% 48
2021
Q2 		$3.05M Sell
38,839
-73,080
-65% -$4.52M 0.38% 40
2021
Q1 		$6.39M Sell
111,919
-60,121
-35% -$4.02M 0.96% 31
2020
Q4 		$14.4M Sell
172,040
-7,389
-4% -$447K 1.73% 19
2020
Q3 		$6.43M Sell
179,429
-1,069
-0.6% -$32.2K 0.93% 34
2020
Q2 		$4.36M Buy
180,498
+17,976
+11% +$423K 0.82% 37
2020
Q1 		$2.85M Buy
162,522
+95,965
+144% +$2M 0.66% 37
2019
Q4 		$1.16M Sell
66,557
-2,307
-3% -$38.4K 0.19% 49
2019
Q3 		$1.05M Sell
68,864
-1,668
-2% -$31.9K 0.26% 45
2019
Q2 		$1.46M Hold
70,532
– – 0.34% 44
2019
Q1 		$1.64M Buy
70,532
+50,632
+254% +$1.06M 0.36% 44
2018
Q4 		$411K Buy
+19,900
New +$361K 0.11% 52

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Mark Asset Management's DNLI Position: Q1 2022 in Review

Mark Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2022, closing a stake of 40,370 shares — an estimated $1.8M sold.

Mark Asset Management first reported a position in DNLI in Q4 2018 and held it in 13 quarters. The position peaked at $14.4M in Q4 2020. 190 funds tracked by Wall St. Rank hold DNLI as of Q1 2022.

  • Mark Asset Management reported no remaining Denali Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Mark Asset Management sold 40,370 Denali Therapeutics shares in Q1 2022, an estimated $1.8M.
  • Mark Asset Management first reported a position in Denali Therapeutics in Q4 2018 and held it in 13 quarters.
  • Mark Asset Management's Denali Therapeutics position peaked at $14.4M in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2022.

Based on Mark Asset Management's 13F filing for Q1 2022, filed 16 May 2022.